A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis

Osteoporosis International

Volumn 7, Issue 5, 1997, Pages 488-495

  Clemmesen, B ^a   Ravn, P ^a   Zegels, B ^b   Taquet, A N ^b   Christiansen, C ^a   Reginster, J Y ^b,c  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bisphosphonates; Postmenopausal osteoporosis; Risedronate

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; FEMALE; FEMUR NECK; FOLLOW UP; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE; LONG TERM CARE; LUMBAR VERTEBRA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE AND BONES; BONE DENSITY; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES;

EID: 0030749171     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004152     Document Type: Article

References (47)

1. Wahner HW, Dunn WL, Riggs BL. Assessment of bone mineral: 1. J Nucl Med 1984;25:1134-41.
2. Conference report. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-50.
3. Riggs BL, Wahner HW, Seeman E, et al. Changes in bone mineral density of the proximal femur and spine with aging: differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest 1982;70:716-23.
4. Cummings SR. Are patients with hip fractures more osteoporotic? Review of evidence. Am J Med 1985;78:487-94.
5. GREES Editorials. Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis. Calcif Tissue Int 1995;57:247-50.
6. Heany RP, Recker RR, Saville PD. Menopausal changes in bone remodelling. J Lab Clin Med 1978;92:964-70.
7. Fenton AJ, Gutteridge DH, Kent GN, et al. Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric, and radiological responses. Clin Endocrinol 1991;34:197-204.
8. Bickerstaff DR, O'Doherty DP, McCloskey EV, et al. Effects of amino-butylidene diphosphonates in hypercalcemia due to malignancy. Bone 1991;12:17-20.
9. Paterson AHG, Ernst DS, Powles TJ, et al. Treatment of skeletal disease in breast cancer with clodronate. Bone 1991;12(Suppl):S25-30.
10. Valkema R, Vismans F-JFE, Papapoulos SE, et al. Maintained improvement m calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989;5:183-92.
11. Thiébaud D, Burckhardt P, Melchior J, et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluroide for osteoporosis occurring in the postmenopause. Osteoporos Int 1994;4:76-83.
12. Reid IR, Wattie DJ, Evans MC, et al. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994;79:1595-9.
13. Giannini S, D'angelo AD, Malvasi L, et al. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 1993;14:137-41.
14. Reginster JY, Lecart MP, Deroisy R, et al. Prevention of postmenopausal bone loss by tiludronate Lancet 1989;2:1469-71.
15. Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996;19:527-33.
16. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
17. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
18. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded threapy followed by one year of open therapy. Am J Med 1993;95:557-67.
19. Harris ST, Gertz BJ, Genant HK, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodelling in early postmenopausal women. J Clin Endocrinol Metab 1993;76:1399-406.
20. Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-52.
21. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal osteoporosis. Bone 1996;18.141-50.
22. Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995;17:383-90.
23. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
24. Khairi MRA, Altman RD, DeRosa GP, et al. Sodium etidronate in the treatment of Paget's disease of bone: a study of long-term results. Ann Intern Med 1977;87:656-63.
25. Proctor & Gamble Pharmaceuticals Inc. Clinical investigator's manual NE-58095, April 1992.
26. McClung M, Bensen W, Bolognese M, et al. Risedronate treatment of postmenopausal women with low bone mass: preliminary data. Osteoporos Int 1996;6(Suppl 1):257.
27. Hansen MA, Hassager C, Overgaard K, et al. Dual-energy X-ray absorptiometry: a precise method of measuring bone mineral density of the lumbar spine. J Nucl Med 1990;31:1156-62.
28. Svendsen OL, Marslew U, Hassager C, Christiansen C. Measurements of bone mineral density of the proximal femur by two commercially available dual-energy X-ray absorptiometric systems. Eur J Nucl Med 1992;19:41-6.
29. Reginster JY, Deroisy R, Zegels B, et al. Long term performance in vitro and in vivo of dual-energy X-ray absorptiometry. Clin Rheum 1995;14:180-6.
30. Haarbo J, Gotfredsen A, Hassager C, Christiansen C. Validation of body composition by dual energy x-ray absorptiometry (DEXA) Clin Physiol 1991;11:331-41.
31. Bjarnason K, Hassager C, Ravn P, Christiansen C. Early postmenopausal diminution of forearm and spinal bone mineral density a cross-sectional study. Osteoporos Int 1995;5:353-8.
32. Nilas L, Borg J, Gotfredsen A, Christiansen C. Comparison of single- and dual-photon absorptiometry in postmenopausal bone mineral loss. J Nucl Med 1985;26:1257-62.
33. Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology. Recommended methods for the determination of four enzymes in blood. Scand J Clin Lab Invest 1974;33:291-306.
34. Johansen JS, Molholm Hansen JE, Christiansen C. A radioimmunoassay for bone Gla protein (BGP) in human plasma. Acta Endocrinol 1987;114:410-6.
35. Rosenquist C, Qvist P. Measurement of a more stable structure of osteocalcin in human serum using two monoclonal antibodies in an enzyme-linked immunosorbent assay (ELISA). Clin Chem 1995;41:1439-45.
36. Podenphant J, Larsen N-E, Christiansen C. An easy and reliable method for determination of urinary hydroxyproline. Clin Chem Acta 1984;142:145-8.
37. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87-96.
38. Bonde M, Qvist P, Fledelius C, et al. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994; 40:2022-5.
39. Bonde M, Qvist P, Fledelius C, et al Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995;80:864-8.
40. Garnero P, Gineyts E, Riou JP, Delmas P. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994;79:780-5.
41. Plosker GL, Goa KL. Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994;47:945-82.
42. Russell RGG, Smith R, Preston C, et al. Diphosphonates in Paget's disease. Lancet 1974;1:894-8.
43. Fleisch H. Bisphosphonates: pharmacolology and use m the treament of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991;42:919-44.
44. Zegels B, Taquet AN, Castell R, et al. Biochemical evidence of antiresorptive effect of risedronate in established osteoporosis. Osteoporos Int 1996;6(Suppl 1):249.
45. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305:556-61.
46. Mitchell DY, Eusebio RA, Heise MA, et al. The effect of dosing regimen on the pharmacokinetics of risedronate administered to healthy subject. J Bone Miner Res 1996;11(Suppl 1):S347.
47. Mortensen L, Bekker P, Ouweland Fvd, et al. Prevention of early postmenopausal bone loss by risedronate: a two year study. J Bone Miner Res 1995;10(Suppl 1):S140.